Romatoid Artrit Tanısıyla Tofasitinib Tedavisi Alan Hastaların Faz 3 ve Uzun Süreli Uzatma (LTE) Çalışmalarındaki Hematolojik Değişikliklerin Analizi
Rheumatology 2017;56:46–57.
In this analysis examining haematological changes after tofacitinib (TOF) treatment in patients with RA from pooled Phase 3 and LTE studies, TOF decreased mean lymphocyte counts and slightly increased mean haemoglobin (Hb) levels. The Phase 3 population included patients from six trials (n=4271) of TOF 5- or 10 mg BID, placebo or active comparator up to 24 months. The LTE population (n=4858) included patients from two studies (of up to 84 months), who had participated in Phase 1, 2 or 3 TOF stud...